Thanks, Nick!

All the credit goes to the entire Boltz team! Join us in this journey! jobs.gem.com/boltz

We will also be hosting Boltz launch parties that will include a demo, drinks, awesome discussions, and a giveaway of free credits. Sign up!
San Francisco, Jan 15th: luma.com/yogmbte1
Boston, Jan 22nd: luma.com/6txhgndf
London, Jan 29th: luma.com/8rar11y4
Virtual, Feb 2nd: luma.com/ttuhzb92

Read more from the following longer-form blogs posts:
- Our company manifesto: boltz.bio/manifesto
- Our platform and agents announcement: boltz.bio/boltzlab
- Our press release with Pfizer: boltz.bio/pfizer-partn...
- Andrew Dunn article on Endpoints: endpoints.news/exclusive-bo...

Sign up to Boltz Lab today and you will also receive credits to start using the platform for free. We can’t wait to see what you build on Boltz Lab! lab.boltz.bio

All of this would not have been possible without first assembling an exceptional team. To support this team, we are honored to announce we’ve raised $28M seed round led by Zetta, Amplify, and a16z along with strategic angels including @clem.hf.co & @matthartman.bsky.social

Over the past few months, we have already seen the success of the new agents and Boltz Lab in the hands of scientists across the field. Whether you are an individual researcher or a company the size of Pfizer, we can’t wait to see what you build with our tools in your hands.

We are also excited to announce a multi-year collaboration with Pfizer, to put Boltz Lab and its agents in the hands of Pfizer scientists, and to work together on new foundation models leveraging Pfizer data.

We’ve focused on optimization + infrastructure so results arrive quickly, we have generous free tiers, and costs are lower than open-source, without users taking on the engineering. We have clear terms: you own your outputs, your data stays secure, and we don’t train on your data

We’ve made these agents the core of Boltz Lab, a new platform designed around real bio/chem workflows, removing adoption bottlenecks like compute cost, scalable infrastructure, and collaborative interfaces.

We have been hard at work building and validating the next generation of small-molecule and protein design agents that more deeply leverage our models driving significant improvements. We’re releasing the first versions of these agents and sharing some great initial results!

We are not a therapeutics company. Our goal is to build a product that allows every scientist to go from a therapeutic hypothesis to a human-ready molecule without leaving their computer. As a first step, we are releasing a preview of Boltz Lab, our platform alongside new AI agents.

We believe the frontier should stay open enough to maximize scientific and patient impact. That’s why we founded Boltz PBC, a Public Benefit Corporation: advance AI for biology through open science, and make it accessible to every scientist building a healthier future.

As researchers, we have seen firsthand the power of open science. Our models, Boltz-1, Boltz-2 and BoltzGen, have already been used by over a hundred thousand scientists in both academia and industry and form the foundation for countless pipelines, agents, and platforms.

AI-powered molecular modeling is advancing fast with the promise of making biology programmable, digitizing experiments, and dramatically speeding up drug discovery. But the field is trending more closed, severely limiting the impact on science and, most importantly, on patients.